Angiotensin Receptor Blockers

Given the equal outcome efficacy but fewer adverse events with ARBs, risk-to-benefit analysis in aggregate indicates that at present there is little, if any, reason to use ACE inhibitors for the treatment of hypertension or its compelling indications - Franz Messerli, MD

Angiotensin Receptor Blockers

image by: De Hammer Alphega Apotheek
     

HWN Recommends

Use of antihypertensive drugs generates pressure-packed debate in COVID-19 era

Since the beginning of the pandemic, everything and its opposite has been said about antihypertensive medications. Used in patients suffering from high blood pressure, these medications were first thought to aggravate the consequences of COVID-19 before being considered as a new therapeutic avenue for the same disease.

As a PhD candidate in pharmaceutical sciences at the faculty of pharmacy and the Institute for Research in Immunology and Cancer in Montréal, I believe it is important to observe the need for rigorous scientific research before disseminating conclusions on such a subject, especially during a health crisis.

The different roles of ACE2

COVID-19…

read full article

Resources

Related Articles

Stay Connected

©2022 | HealthWorldNet, Inc. | 110479

Last Updated : Friday, November 4, 2022